We advocate for the construction of a new detector element at the LHCb experiment, designed to search for displaced decays of beyond Standard Model long-lived particles, taking advantage of a large ...shielded space in the LHCb cavern that is expected to soon become available. We discuss the general features and putative capabilities of such an experiment, as well as its various advantages and complementarities with respect to the existing LHC experiments and proposals such as SHiP and MATHUSLA. For two well-motivated beyond Standard Model benchmark scenarios-Higgs decay to dark photons and B meson decays via a Higgs mixing portal-the reach either complements or exceeds that predicted for other LHC experiments.
Run 5 of the high-luminosity LHC era (and beyond) may provide new opportunities to search for physics beyond the standard model at interaction point 2. In particular, taking advantage of the existing ...ALICE detector and infrastructure provides an opportunity to search for displaced decays of beyond standard model long-lived particles. While this proposal may well be preempted by ongoing ALICE physics goals, examination of its potential new physics reach provides a compelling comparison with respect to other long-lived particle proposals. In particular, full event reconstruction and particle identification could be possible by making use of the existing L3 magnet and ALICE time projection chamber. For several well-motivated portals, the reach competes with or exceeds the sensitivity of MATHUSLA and SHiP, provided that a total integrated luminosity of approximately 100 fb−1 could be delivered to interaction point 2.
We review the status of, and prospects for, real-time data processing for collider experiments in experimental High Energy Physics. We discuss the historical evolution of data rates and volumes in ...the field and place them in the context of data in other scientific domains and commercial applications. We review the requirements for real-time processing of these data, and the constraints they impose on the computing architectures used for such processing. We describe the evolution of real-time processing over the past decades with a particular focus on the Large Hadron Collider experiments and their planned upgrades over the next decade. We then discuss how the scientific trends in the field and commercial trends in computing architectures may influence real-time processing over the coming decades.
Upgrades to the LHCb computing infrastructure in the first long shutdown of the LHC have allowed for high quality decay information to be calculated by the software trigger making a separate offline ...event reconstruction unnecessary. Furthermore, the storage space of the triggered candidate is an order of magnitude smaller than the entire raw event that would otherwise need to be persisted. Tesla is an application designed to process the information calculated by the trigger, with the resulting output used to directly perform physics measurements.
Expression of interest for the CODEX-b detector Aielli, Giulio; Ben-Haim, Eli; Cardarelli, Roberto ...
The European physical journal. C, Particles and fields,
12/2020, Volume:
80, Issue:
12
Journal Article
Peer reviewed
Open access
This document presents the physics case and ancillary studies for the proposed CODEX-b long-lived particle (LLP) detector, as well as for a smaller proof-of-concept demonstrator detector, CODEX-
β
, ...to be operated during Run 3 of the LHC. Our development of the CODEX-b physics case synthesizes ‘top-down’ and ‘bottom-up’ theoretical approaches, providing a detailed survey of both minimal and complete models featuring LLPs. Several of these models have not been studied previously, and for some others we amend studies from previous literature: In particular, for gluon and fermion-coupled axion-like particles. We moreover present updated simulations of expected backgrounds in CODEX-b’s actively shielded environment, including the effects of shielding propagation uncertainties, high-energy tails and variation in the shielding design. Initial results are also included from a background measurement and calibration campaign. A design overview is presented for the CODEX-
β
demonstrator detector, which will enable background calibration and detector design studies. Finally, we lay out brief studies of various design drivers of the CODEX-b experiment and potential extensions of the baseline design, including the physics case for a calorimeter element, precision timing, event tagging within LHCb, and precision low-momentum tracking.
A
bstract
This report details the capabilities of LHCb and its upgrades towards the study of kaons and hyperons. The analyses performed so far are reviewed, elaborating on the prospects for some key ...decay channels, while proposing some new measurements in LHCb to expand its strangeness research program.
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant ...progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, and a clinically meaningful overall survival (OS) effect in PD-L1-positive aTNBC. The phase III KEYNOTE-355 trial adding pembrolizumab to chemotherapy for aTNBC showed similar PFS effects. IMpassion131 evaluated first-line atezolizumab–paclitaxel in aTNBC.
Eligible patients no prior systemic therapy or ≥12 months since (neo)adjuvant chemotherapy were randomised 2:1 to atezolizumab 840 mg or placebo (days 1, 15), both with paclitaxel 90 mg/m2 (days 1, 8, 15), every 28 days until disease progression or unacceptable toxicity. Stratification factors were tumour PD-L1 status, prior taxane, liver metastases and geographical region. The primary endpoint was investigator-assessed PFS, tested hierarchically first in the PD-L1-positive immune cell expression ≥1%, VENTANA PD-L1 (SP142) assay population, and then in the ITT population. OS was a secondary endpoint.
Of 651 randomised patients, 45% had PD-L1-positive aTNBC. At the primary PFS analysis, adding atezolizumab to paclitaxel did not improve investigator-assessed PFS in the PD-L1-positive population hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.60-1.12; P = 0.20; median PFS 6.0 months with atezolizumab–paclitaxel versus 5.7 months with placebo–paclitaxel. In the PD-L1-positive population, atezolizumab–paclitaxel was associated with more favourable unconfirmed best overall response rate (63% versus 55% with placebo–paclitaxel) and median duration of response (7.2 versus 5.5 months, respectively). Final OS results showed no difference between arms (HR 1.11, 95% CI 0.76-1.64; median 22.1 months with atezolizumab–paclitaxel versus 28.3 months with placebo–paclitaxel in the PD-L1-positive population). Results in the ITT population were consistent with the PD-L1-positive population. The safety profile was consistent with known effects of each study drug.
Combining atezolizumab with paclitaxel did not improve PFS or OS versus paclitaxel alone.
NCT03125902.
•The phase III IMpassion131 trial evaluated atezolizumab combined with paclitaxel as first-line therapy for aTNBC.•The primary endpoint was investigator-assessed PFS, tested hierarchically in the PD-L1+ and then ITT populations.•Neither PFS nor OS was improved with the combination of atezolizumab plus paclitaxel in either population.•These findings may result from imbalances in prognostic features or chance findings in a relatively small trial.•IMpassion131 results highlight the need for further research into immunotherapy for TNBC.
PDF
